Pfizer (PFE) Reports Top-Line Results of ABRYSVO for RSV in Immunocompromised Adults
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Pfizer (PFE) PT Raised to $30 at Citi
August 13, 2024 4:41 PM EDTCiti analyst Andrew Baum raised the price target on Pfizer (NYSE: PFE) to $30.00 (from $28.00) while maintaining a Neutral rating.
The analyst comments "We update our forecasts post 2Q24 to incorporate latest results and guidance, and sales, prescription, and currency trends. Our 2024E non-GAAP EPS... More
